10 more years!

In preparation for the closing session of the upcoming ILSI biomed conference, dealing with the issue of local management vs. international management, ILSI-Biomed is conducting a survey to assess current attitudes towards management of an Israeli start up companies.

The session will be led by Dr Dalia Megiddo.

If you could answer a few short questions, your name and company will be kept confidential.

1. Is in necessary at some point in an Israeli healthcare company’s life cycle, to recruit a CEO who is part of the US market and culture, preferably a US-born and raised CEO (as opposed to an Israeli CEO with less experience in the US market)? Yes/No Comments_____________
2. Is in necessary at some point in an Israeli healthcare life cycle, to recruit a CEO who is part of the Europe market and culture, preferably a European-born and raised CEO (as opposed to an Israeli CEO with less experience in the European market)? Yes/No Comments ________
3. If so, at what stage of the company’s life should this change be made? (R&D / Clinical trials / advanced clinical trials / sales) Comment _____________
4. What is the main contribution of an American/Europe CEO to an Israeli company? (Relationships and networking / experience in running a healthcare company / deep understanding of the US market / has no specific advantage over an Israeli CEO)
5. If you have experienced a multi-cultural management system, feel free to give you opinion on the best ways to raise the chances of such an arrangement actually benefiting the company
_____________________________________________________________

ILSI will appreciate if you respond as soon as possible to michal@ilsi.org.il or sima@ilsi.org.il

Tweet

Share on Facebook

Popularity: 29% [?]